About madrigal pharmaceuticals inc - MDGL
Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of therapeutics for metabolic dysfunction-associated steatohepatitis. The company was founded by Rebecca A. Taub, Frederick Bernard Craves, and Edward Chiang on March 10, 2000 and is headquartered in West Conshohocken, PA.
MDGL At a Glance
Madrigal Pharmaceuticals, Inc.
Four Tower Bridge
West Conshohocken, Pennsylvania 19428
| Phone | 1-267-824-2827 | Revenue | 958.40M | |
| Industry | Pharmaceuticals: Major | Net Income | -288,284,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 432.053% | |
| Fiscal Year-end | 12 / 2026 | Employees | 915 | |
| View SEC Filings |
MDGL Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 13.631 |
| Price to Book Ratio | 22.071 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -41.607 |
| Enterprise Value to Sales | 12.963 |
| Total Debt to Enterprise Value | 0.028 |
MDGL Efficiency
| Revenue/Employee | 1,047,434.973 |
| Income Per Employee | -315,064.481 |
| Receivables Turnover | 7.127 |
| Total Asset Turnover | 0.833 |
MDGL Liquidity
| Current Ratio | 4.015 |
| Quick Ratio | 3.774 |
| Cash Ratio | 3.186 |
MDGL Profitability
| Gross Margin | 93.984 |
| Operating Margin | -31.312 |
| Pretax Margin | -30.08 |
| Net Margin | -30.08 |
| Return on Assets | -25.048 |
| Return on Equity | -42.486 |
| Return on Total Capital | -30.335 |
| Return on Invested Capital | -31.64 |
MDGL Capital Structure
| Total Debt to Total Equity | 57.68 |
| Total Debt to Total Capital | 36.58 |
| Total Debt to Total Assets | 27.599 |
| Long-Term Debt to Equity | 57.511 |
| Long-Term Debt to Total Capital | 36.473 |